What Zetta Genomics does

Zetta Genomics is a UK-based genomic data management company founded in 2018 as a spin-out from the University of Cambridge and Genomics England. The company developed XetaBase, a genomic-native tertiary analysis platform built on the open-source OpenCB software foundation, which aggregates, stores, retrieves, annotates, visualises, and interprets genomic data at population scale — from single-sample VCF files to hundreds of thousands of whole genomes. The platform supports multi-omics including whole genome/exome sequencing, long-read data, transcriptomics, epigenomics, proteomics, and structural variants, with federated architecture enabling decentralised data sharing across borders and institutions.

Zetta serves four primary customer segments: clinical diagnostics organisations, national and regional healthcare initiatives (including the NHS Genomics Medicine Service and newborn screening), biopharmaceutical companies for biomarker and therapeutic discovery, and academic research institutions. Named customers include Genomics England, NHS, Children's Hospital of Los Angeles, SJD Barcelona, MRC Human Genetics Unit at the University of Edinburgh, and TriNetX. The company holds MHRA registration with UKCA marking and ISO 27001 Stage 2 certification, positioning it for regulated clinical deployments.

The business operates on a quote-based enterprise subscription model with platform licensing of XetaBase as the core revenue stream, complemented by managed services, SaaS products distributed through AWS and Azure Marketplaces, and clinical integration services. Distribution combines direct enterprise field sales (led by a CRO and CCO) with channel partnerships (IBM, GBM, Gulf Scientific) and marketplace listings. The company raised approximately £6.2 million across three seed rounds between 2022 and 2024, with offices in Cambridge (UK) and Valencia (Spain). In April 2026, TriNetX acquired key Zetta assets including the XetaBase platform.

Name

Zetta Genomics

Legal name

Zetta Genomics Limited

Website

https://zettagenomics.com

Company type

Private

Founded year

2018

Operating status

Acquired

Headcount range

11–50 employees

Short description

Zetta Genomics is a UK-based genomic data management company offering the XetaBase platform for population-scale tertiary analysis of genomic and multi-omic data, serving clinical diagnostics, national healthcare initiatives, biopharmaceutical firms, and research institutions globally.

Ownership category

akta.pro rank

Product category

Genomic Data Management Software

NAICS

Software Publishers (5132), Custom Computer Programming Services (541511), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (5182)

SIC

Services-Computer Programming Services (7371)

akta.pro primary industry

Bioinformatics & Multi-omics Analysis Software (HLAGAJAD)

akta.pro secondary industries

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Genomic data management
• Clinical genomics software
• Multiomics data platform
• Variant annotation services
• Population genomics platform

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Platform Licensing (XetaBase): Licensing of XetaBase genomic data management platform to healthcare systems, research institutions, and life sciences companies for managing and analysing genomic data.
2. SaaS Products (AWS/Azure Marketplace): Cloud-based SaaS variant store and annotation store products available through AWS Marketplace and Azure Marketplace, providing scalable genomic data storage and analysis as a service.
3. Managed Services: First managed service customer onboarded in 2019, providing ongoing managed service support for genomic data management.
4. Clinical Integrations: Streamlined connectivity with EHRs, LIMS, reporting tools and downstream clinical systems, enabling genomics to flow into clinical decision pathways.

Pricing tiers

Go-to-market motion4 records

Distribution channels4 records

Marketing channels8 records

Core offering

Zetta Genomics develops and sells XetaBase, a genomic-native tertiary analysis platform that aggregates, integrates, stores, retrieves, annotates, visualizes, analyzes, and interprets large-scale genomic and multi-omics data. Built on the open-source OpenCB platform, the software scales from single-sample VCF to hundreds of thousands of whole genomes, serving clinical diagnostics labs, healthcare population genomics programs, biopharma companies, and research institutions. The company also offers SaaS Variant Store and Annotation Store products via AWS Marketplace.

Product overview

Zetta Genomics offers a unified genomic data management platform centered on XetaBase, built on the open-source OpenCB software. The product portfolio includes the core XetaBase platform for tertiary genomic analysis, supplemented by specialised modules including the Xeta Variant Store and Xeta Variant Annotation Store for SaaS deployment on AWS, and CellBase for integrated knowledge and annotation. Solutions are segmented by industry vertical: Clinical Diagnostics, Healthcare Initiatives, Biopharmaceutical, and Research Institutions. The platform handles genomic data aggregation, storage, retrieval, annotation, visualisation, and interpretation at population scale, supporting both cloud-native and on-premises deployment with full clinical workflow automation capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• XetaBase A genomic-native tertiary analysis platform built on open-source OpenCB software that aggregates, integrates, stores, retrieves, annotates, visualizes, analyses and interprets genomic data at population scale. Supports both research and clinical applications with cloud-native and on-premises deployment options, scaling from single sample VCF to hundreds of thousands of whole genomes. Target users are clinical diagnostic laboratories, healthcare population genomics programmes, biopharma companies, and research institutions.
• Xeta Variant Store A secure, high-performance cloud-native repository for genomic variant data, built to handle population-scale volumes with harmonised, query-ready data structures supporting fast clinical interpretation, cohort analysis, and downstream discovery. Delivered as SaaS on AWS Marketplace and targeted at enterprise customers requiring managed variant storage at scale.
• Xeta Variant Annotation Store A SaaS-based annotation engine that cross-references variants against multiple genomic knowledge bases, continuously updated and integrated via APIs with 60+ annotation databases. Designed for enterprise clinical and research teams that need to ensure they work from the most current and clinically relevant evidence with automated enrichment and real-time updates.

Quantifiable outcome

• Scales to 500,000 genomes under management
• +4 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability5 records

Feature10 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• TriNetXcoreStrategic or Co-development Partner · 7 April 2026World's leading federated health data network. Collaboration since 2024 on federated querying across genomic and phenotypic data. TriNetX acquired key Zetta assets including XetaBase platform in April 2026 to expand multiomic capabilities.
• MicrosoftcoreStrategic or Co-development Partner · 8 February 2024Strategic partnership with Microsoft as part of industry leaders collaboration. XetaBase platform integration and expansion plans through Microsoft ecosystem.
• FujitsucoreStrategic or Co-development Partner · 8 February 2024Strategic partnership with Fujitsu for industry collaboration and market expansion in healthcare technology sector.
• IQVIAcoreStrategic or Co-development Partner · 8 February 2024Strategic partnership with IQVIA for healthcare industry collaboration, bringing genomic data capabilities to pharmaceutical and healthcare clients.
• University of CambridgecoreStrategic or Co-development Partner · 1 January 2018Zetta Genomics spun out from University of Cambridge in 2018. Ignacio Medina serves as Head of Computational Biology Lab at Cambridge Research Computing Service.
• IBMminorGTM or Marketing PartnerIBM Watson Discovery integration mentioned. IBM partners able to demonstrate Zetta products at PMFG Sidra Conference.
• GBM (Gulf Business Machines)minorGTM or Marketing PartnerRegional partner for Gulf region able to demonstrate Zetta products and discuss partnership at PMFG Sidra Conference.
• Gulf ScientificminorGTM or Marketing PartnerRegional partner for Middle East able to demonstrate Zetta products and discuss partnership at PMFG Sidra Conference.
• AWS (Amazon Web Services)coreTechnology or IntegrationAWS Marketplace listing for SaaS Variant Store and Annotation Store products. Zetta positioned as preferred partner following AWS HealthOmics closure to new customers. XetaBase launched on AWS alongside Azure.
• Azure (Microsoft)coreTechnology or IntegrationAzure Marketplace listing for XetaBase platform. Cloud deployment option alongside AWS for customers preferring Microsoft cloud infrastructure.
• Genomics EnglandcoreStrategic or Co-development PartnerZetta Genomics spun out from Genomics England. XetaBase originally inspired by challenges encountered during 100,000 Genomes Project. Technology proven at scale in flagship population genomics project.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• DNAnexus: DNAnexus provides a cloud-based genomic and biomedical data management and analysis platform serving clinical, research and pharmaceutical customers. It is the closest direct peer to Zetta's XetaBase in scale, deployment model and target customer base.
• SOPHiA Genetics: SOPHiA Genetics operates a clinical genomics platform using AI to analyse multiomic data for hospitals and labs. It competes head-to-head with XetaBase in clinical variant interpretation; Zetta NED Bram Goorden is an SOPHiA alumnus.
• Congenica: Congenica provides clinical genomic data interpretation software for rare disease and cancer diagnostics. It is a direct peer in the clinical tertiary analysis category; Zetta's Head of Product previously worked at Congenica.
• BC Platforms: BC Platforms offers genomic and clinical data management infrastructure with a focus on federated data and real-world evidence. It is a direct peer in population-scale genomics platforms and federated data sharing.
• WuXi NextCODE (now Genuity Science): WuXi NextCODE built a genomics data and analytics platform used for clinical trial sequencing and population genomics. Zetta CCO Mark Hughes led large-scale clinical trial sequencing projects at WuXi NextCODE, and the companies compete for similar biopharma accounts.
• Lifebit Biotech: Lifebit provides a federated genomics and biomedical data platform with Trusted Research Environments. It is a direct peer in the federated, cloud-native tertiary analysis category, particularly for national genomics initiatives.
• Fabric Genomics (GeneDx): Fabric Genomics (now part of GeneDx) provides AI-driven clinical genomic interpretation software. It is a direct peer in clinical tertiary analysis and variant interpretation for hospital and reference-lab customers.
• PierianDx (now part of Elsevier): PierianDx provided a clinical genomics interpretation platform for hospital labs before being acquired by Elsevier. It was a direct peer in clinical tertiary analysis, EHR integration and variant interpretation workflows.

Broad incumbents

• Illumina (Connected Software / Illumina Connected Analytics): Illumina is the dominant sequencing instrument vendor and increasingly offers cloud-based genomic data management and analytics through Illumina Connected Analytics and DRAGEN. It is a broad incumbent that competes on the platform layer in addition to sequencing.

Others

• Genomics England: Genomics England delivered the 100,000 Genomes Project and now operates the NHS Genomic Medicine Service. It is both a Zetta partner/customer and a public-sector reference customer whose internal data platform strategy shapes Zetta's UK opportunity.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/zetta_genomics
• LinkedInlinkedin.com/company/zetta-genomics-cambridge

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zetta Genomics